Decreased adiponectin level is associated with aggressive phenotype of tongue squamous cell carcinoma

Cancer Science

Volumn 104, Issue 2, 2013, Pages 206-213

  Guo, Xiao Hong ^a   Wang, Jin Yu ^a   Gao, Yan ^a   Gao, Min ^a   Yu, Guang Yan ^a   Xiang, Ruo Lan ^a   Li, Li ^a   Yang, Ning Yan ^a   Cong, Xin ^a   Xu, Xiao Yan ^b   Li, Sheng Lin ^a   Peng, Xin ^a   Wu, Li Ling ^a  

^a PEKING UNIVERSITY SCHOOL AND HOSPITAL OF STOMATOLOGY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN;

ADULT; ARTICLE; CANCER RISK; CANCER SIZE; CARDIOVASCULAR DISEASE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRINKING BEHAVIOR; FEMALE; HUMAN; HUMAN CELL; HYPOADIPONECTINEMIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; SMOKING; TONGUE CARCINOMA; WESTERN BLOTTING;

ADIPONECTIN; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PHENOTYPE; RECEPTORS, ADIPONECTIN; RISK FACTORS; TONGUE NEOPLASMS;

EID: 84873698010     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12077     Document Type: Article

References (50)

1. Yuen AP, Lam KY, Chan AC et al. Clinicopathological analysis of elective neck dissection for N0 neck of early oral tongue carcinoma. Am J Surg 1999; 177: 90-2.
2. Myers JN, Greenberg JS, Mo V, Roberts D. Extracapsular spread. A significant predictor of treatment failure in patients with squamous cell carcinoma of the tongue. Cancer 2001; 92: 3030-6.
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010; 60: 277-300.
4. Rodriguez T, Altieri A, Chatenoud L et al. Risk factors for oral and pharyngeal cancer in young adults. Oral Oncol 2004; 40: 207-13.
5. Sarode SC, Sarode GS, Karmarkar S, Tupkari JV. A new classification for potentially malignant disorders of the oral cavity. Oral Oncol 2011; 47: 920-1.
6. Madsen EL, Rissanen A, Bruun JM et al. Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol 2008; 158: 179-87.
7. Hotta K, Funahashi T, Arita Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-9.
8. Hui X, Lam KS, Vanhoutte PM, Xu A. Adiponectin and cardiovascular health: an update. Br J Pharmacol 2012; 165: 574-90.
9. Yun JE, Sull JW, Lee HY et al. Serum adiponectin as a useful marker for metabolic syndrome in type 2 diabetic patients. Diabetes Metab Res Rev 2009; 25: 259-65.
10. Tworoger SS, Eliassen AH, Kelesidis T et al. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab 2007; 92: 1510-6.
11. Cust AE, Kaaks R, Friedenreich C et al. Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women. J Clin Endocrinol Metab 2007; 92: 255-63.
12. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 2005; 97: 1688-94.
13. Grossmann ME, Nkhata KJ, Mizuno NK, Ray A, Cleary MP. Effects of adiponectin on breast cancer cell growth and signaling. Br J Cancer 2008; 98: 370-9.
14. Petridou ET, Mitsiades N, Gialamas S et al. Circulating adiponectin levels and expression of adiponectin receptors in relation to lung cancer: two case-control studies. Oncology 2007; 73: 261-9.
15. Dalamaga M, Migdalis I, Fargnoli JL et al. Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case-control study. Cancer Causes Control 2009; 20: 625-33.
16. Sadik NA, Ahmed A, Ahmed S. The significance of serum levels of adiponectin, leptin, and hyaluronic acid in hepatocellular carcinoma of cirrhotic and noncirrhotic patients. Hum Exp Toxicol 2012; 31: 311-21.
17. Gialamas SP, Petridou ET, Tseleni-Balafouta S et al. Serum adiponectin levels and tissue expression of adiponectin receptors are associated with risk, stage, and grade of colorectal cancer. Metabolism 2011; 60: 1530-8.
18. Wei KJ, Zhang L, Yang X et al. Overexpression of cytokeratin 17 protein in oral squamous cell carcinoma in vitro and in vivo. Oral Dis 2009; 15: 111-7.
19. Sobin LH, Wittekind C. International Union Against Cancer (UICC). TNM Classification of Malignant Tumours, 6th edn. New York: Wiley-Liss, 2002.
20. Barnes L, Eveson JW, Reichart P, Sidransky D. World Health Organization Classification of Tumours. Pathology and Genetics of Head and Neck Tumours. Lyon: IARC Press, 2005.
21. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987; 8: 138-40.
22. Camisasca DR, Honorato J, Bernardo V et al. Expression of Bcl-2 family proteins and associated clinicopathologic factors predict survival outcome in patients with oral squamous cell carcinoma. Oral Oncol 2009; 45: 225-33.
23. Cong X, Zhang Y, Shi L et al. Activation of transient receptor potential vanilloid subtype 1 increases expression and permeability of tight junction in normal and hyposecretory submandibular gland. Lab Invest 2012; 92: 753-68.
24. Spyridopoulos TN, Petridou ET, Skalkidou A, Dessypris N, Chrousos GP, Mantzoros CS. Low adiponectin levels are associated with renal cell carcinoma: a case-control study. Int J Cancer 2007; 120: 1573-8.
25. Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S. Prostate cancer and adiponectin. Urology 2005; 65: 1168-72.
26. Yildirim A, Bilici M, Cayir K, Yanmaz V, Yildirim S, Tekin SB. Serum adiponectin levels in patients with esophageal cancer. Jpn J Clin Oncol 2009; 39: 92-6.
27. Sjostrom L, Gummesson A, Sjostrom CD et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol 2009; 10: 653-62.
28. Gorsky M, Epstein JB, Oakley C, Le ND, Hay J, Stevenson-Moore P. Carcinoma of the tongue: a case series analysis of clinical presentation, risk factors, staging, and outcome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 98: 546-52.
29. Nakajima TE, Yamada Y, Hamano T et al. Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol 2009; 44: 685-90.
30. Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, Nagawa H. Plasma adiponectin and gastric cancer. Clin Cancer Res 2005; 11: 466-72.
31. Yu JG, Javorschi S, Hevener AL et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002; 51: 2968-74.
32. Banga A, Unal R, Tripathi P et al. Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids. Am J Physiol Endocrinol Metab 2009; 296: E480-9.
33. Nakamura T, Kawachi K, Saito Y et al. Effects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertension. Int Heart J 2009; 50: 501-12.
34. Kotani K, Hazama A, Hagimoto A et al. Adiponectin and smoking status: a systematic review. J Atheroscler Thromb 2012; 19: 787-94.
35. Nishise Y, Saito T, Makino N et al. Relationship between alcohol consumption and serum adiponectin levels: the Takahata study-A cross-sectional study of a healthy Japanese population. J Clin Endocrinol Metab 2010; 95: 3828-35.
36. Soliman PT, Wu D, Tortolero-Luna G et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer 2006; 106: 2376-81.
37. Waki H, Yamauchi T, Kamon J et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 2003; 278: 40352-63.
38. Korner A, Pazaitou-Panayiotou K, Kelesidis T et al. Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab 2007; 92: 1041-8.
39. Sumie S, Kawaguchi T, Kuromatsu R et al. Total and high molecular weight adiponectin and hepatocellular carcinoma with HCV infection. PLoS ONE 2011; 6: e26840.
40. Aleksandrova K, Boeing H, Jenab M et al. Total and high-molecular weight adiponectin and risk of colorectal cancer: the European Prospective Investigation into Cancer and Nutrition Study. Carcinogenesis 2012; 33: 1211-8.
41. Kotani K, Wakai K, Shibata A et al. Serum adiponectin multimer complexes and liver cancer risk in a large cohort study in Japan. Asian Pac J Cancer Prev 2009; 10(Suppl): 87-90.
42. Barresi V, Tuccari G, Barresi G. Adiponectin immunohistochemical expression in colorectal cancer and its correlation with histological grade and tumour microvessel density. Pathology 2009; 41: 533-8.
43. Haksever M, Inancli HM, Tuncel U et al. The effects of tumor size, degree of differentiation, and depth of invasion on the risk of neck node metastasis in squamous cell carcinoma of the oral cavity. Ear Nose Throat J 2012; 91: 130-5.
44. Karaduman M, Bilici A, Ozet A, Sengul A, Musabak U, Alomeroglu M. Tissue levels of adiponectin in breast cancer patients. Med Oncol 2007; 24: 361-6.
45. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 439-51.
46. Sugiyama M, Takahashi H, Hosono K et al. Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int J Oncol 2009; 34: 339-44.
47. Kim AY, Lee YS, Kim KH et al. Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Mol Endocrinol 2010; 24: 1441-52.
48. Ogunwobi OO, Beales IL. Globular adiponectin, acting via adiponectin receptor-1, inhibits leptin-stimulated oesophageal adenocarcinoma cell proliferation. Mol Cell Endocrinol 2008; 285: 43-50.
49. Wang Y, Lam JB, Lam KS et al. Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 2006; 66: 11462-70.
50. Bub JD, Miyazaki T, Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun 2006; 340: 1158-66.